Amgen Inc. Stock: +4.57% at Close, Driven by Wall Street's Rebound
On November 11, 2025, the stock of biopharmaceutical giant Amgen recorded a notable increase, closing at $338.45 with a gain of 4.57% for the day. This rise is part of a catch-up movement in the American stock markets, which began a robust rebound after experiencing turbulence the previous week. The macroeconomic environment, marked by the prospect of resolving the longest shutdown in American history, contributed to reinvigorating trading. With a volume of over 3.1 million shares traded, representing 0.58% of the capitalization, Amgen actively participated in this upward movement.
Daily Performance on November 11
On the day of November 11, Amgen benefited from a positive dynamic affecting the entire American stock market. The stock advanced by 4.57%, a significant gain reflecting investors' appetite for healthcare sector stocks during this period of macroeconomic volatility. The trading volume remains moderate compared to the stock's capitalization, suggesting a balanced participation in the day's movements. In terms of longer-term performance, the stock shows a year-to-date increase of 5.17% for 2025, a modest evolution compared to the 11.30% gain shown by the Dow Jones index over the same period. In the short term, the dynamics are more pronounced: Amgen has recorded a gain of 14.07% over the past five days, indicating a recent acceleration in purchases. This weekly sequence contrasts with the relative stability observed over the year, indicating a concentration of bullish movements around recent events.
Context of the November 11 Rebound
The rebound on November 11 occurred in a context of resolution of budgetary tensions that had paralyzed the markets for several weeks. An agreement reached the day before in the Senate to end the blockade of federal public services allowed investors to anticipate an upcoming normalization. Although this agreement still needs to be approved by the House of Representatives, where Republicans hold the majority, and then signed into law by President Donald Trump, its conclusion marked a psychological turning point. Wall Street had experienced erratic movements beforehand, fueled by geopolitical fears and persistent questions about the trajectory of interest rates. The rebound of the day is thus explained less by specific data related to the healthcare sector than by this context of easing regulatory uncertainties. The Dow Jones advanced by 0.81% on November 11 according to market data, while the S&P 500 recorded an increase of 1.54%, placing Amgen slightly above this general dynamic. The stock also benefited from an upward revision of its price targets: Deutsche Bank raised its target price from $280 to $285, reflecting sustained confidence in the company's fundamentals.
